NASDAQ · OKUR
Healthcare · Biotechnology
$3.94
Up+$0.01 (+0.25%)
Updated Aug 22, 2026, 2:33 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
OKUR closed at $3.94 after 21 trading sessions, down 4.37% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $3.95 | $4.0728 | $3.90 | $3.94 | 59.91K |
| Aug 20, 2026 | $4.04 | $4.043 | $3.78 | $3.93 | 103.52K |
| Aug 19, 2026 | $4.29 | $4.42 | $4.07 | $4.08 | 166.17K |
| Aug 18, 2026 | $4.11 | $4.27 | $3.99 | $4.21 | 108.17K |
| Aug 17, 2026 | $3.97 | $4.28 | $3.85 | $4.11 | 228.7K |
| Aug 14, 2026 | $3.90 | $4.13 | $3.83 | $3.99 | 216.7K |
| Aug 13, 2026 | $3.95 | $4.09 | $3.86 | $3.90 | 94.05K |
| Aug 12, 2026 | $4.10 | $4.10 | $3.91 | $3.93 | 54.48K |
| Aug 11, 2026 | $4.07 | $4.11 | $3.95 | $4.09 | 83.39K |
| Aug 10, 2026 | $4.07 | $4.1708 | $3.98 | $4.06 | 144.01K |
| Aug 7, 2026 | $4.24 | $4.26 | $4.01 | $4.14 | 85.01K |
| Aug 6, 2026 | $4.17 | $4.27 | $3.90 | $4.15 | 85.94K |
| Aug 5, 2026 | $4.13 | $4.3315 | $3.8801 | $4.16 | 250.24K |
| Aug 4, 2026 | $4.11 | $4.49 | $4.09 | $4.10 | 201.96K |
| Aug 3, 2026 | $3.90 | $4.08 | $3.75 | $4.02 | 160.23K |
| Jul 31, 2026 | $3.99 | $4.005 | $3.72 | $3.82 | 239.64K |
| Jul 30, 2026 | $3.925 | $4.09 | $3.88 | $4.00 | 62.4K |
| Jul 29, 2026 | $4.00 | $4.085 | $3.83 | $3.95 | 82.49K |
| Jul 28, 2026 | $4.06 | $4.30 | $3.735 | $3.95 | 96.54K |
| Jul 27, 2026 | $4.19 | $4.38 | $4.01 | $4.05 | 82.67K |
| Jul 24, 2026 | $4.24 | $4.29 | $4.01 | $4.12 | 186.01K |
The latest Smart Investors Daily articles mentioning OKUR.
OKUR research
Company profile and research snapshot.
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Oppenheimer | Outperform | — |
| Jul 20, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 16, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 26, 2025 | HC Wainwright & Co. | Buy | — |
| Mar 18, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 14, 2026
Oppenheimer analyst Leland Gershell reiterates OnKure Therapeutics (NASDAQ:OKUR) with a Outperform and lowers the price target from $30 to $14.
Benzinga · Aug 4, 2026
OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.54) by 41.51 percent. This is a 72.81 percent increase over losses of $(1.14) per share
Benzinga · Aug 4, 2026
https://www.sec.gov/Archives/edgar/data/1637715/000119312526332839/okur_424b5-20260804.htm
Benzinga · Jul 20, 2026
HC Wainwright & Co. analyst Robert Burns maintains OnKure Therapeutics (NASDAQ:OKUR) with a Buy and lowers the price target from $27 to $21.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OKUR.
